Theratome Bio

Theratome Bio operates at the intersection of regenerative medicine and artificial intelligence, developing therapeutic solutions that address critical unmet needs in transplantation and ophthalmology. The company's development-stage pipeline leverages advanced computational methods to optimize biological formulations, creating a differentiated app... roach to drug discovery and development that combines machine learning insights with cellular biology expertise. The company's core focus centers on two primary therapeutic areas with substantial clinical impact. In organ transplantation, Theratome Bio develops preservation technologies designed to extend viable transplant windows and improve graft outcomes. Simultaneously, the company addresses dry eye disease through targeted therapeutic interventions. This dual-track approach reflects a strategic commitment to conditions where current treatment options remain limited or inadequate. Theratome Bio's proprietary Secretome platform represents the technical foundation of its therapeutic strategy. This technology platform generates disease-specific formulations engineered for rapid bioavailability and consistent performance across manufacturing batches. The platform's modular design enables tailored applications across multiple indications, providing flexibility as the company evaluates expansion opportunities into additional therapeutic areas including respiratory distress, neurodegenerative conditions, and cerebrovascular disease.Read More